Myeloperoxidase, a risk indicator for cardiovascular disease
CA 2440978 C · Owner: Hazen, Stanley · Inventors: Hazen, Stanley; Zhang, Renliang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment the diagnostic , test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine nitrotyrosine, methionine …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 2, 2002 and granted April 2, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 2, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 2, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.